Tharimmune, INC 10-K annual reports

Canton Strategic Holdings, Inc. has completed a major strategic shift from biotechnology to a digital asset treasury strategy focused on Canton Coin and the Canton Network, raising over $537 million in capital.

Tharimmune, Inc. releases its 2024 annual report, detailing clinical advancements and financial results, while acknowledging substantial doubt about its ability to continue as a going concern.

Tharimmune, Inc., a clinical-stage biotechnology company, released its 2023 annual report, highlighting progress in its pipeline and financial position.